This convergence mechanism plays a central role in tumor progression, tissue regeneration, and drug-induced cellular injury across physiological and pathological contexts, providing a theoretical basis for combined therapies targeting HMGCR (e.g., statins) or its downstream pathways. This evidence concerns the gene HMGCR and neoplasm.